tbuckley/cabot-search huggingface dataset:
SAT-413 Cardiovascular disease risk, liver outcomes, and statin use among adults with metabolic dysfunction-associated steatotic liver disease
Authors: Arunkumar Krishnan, Diptasree Mukherjee, Aldanah Althwanay, Faisal Abaalkhail, Waleed K Al-Hamoudi, Saleh A Alqahtani
Journal: Journal of Hepatology (2025)
Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics
Authors: Mengke Xu, Bo Xu
Journal: Molecular Cancer (2025)

Abstract Protein lipidation is a pivotal post-translational modification that increases protein hydrophobicity and influences their function, localization, and interaction network. Emerging evidence has shown significant roles of lipidation in the tumor microenvironment (TME). However, a comprehensive review of this topic is lacking. In this review, we present an integrated and in-depth literature review of protein lipidation in the context of the TME. Specifically, we focus on three major lipidation modifications: S- prenylation, S- palmitoylation, and N- myristoylation. We emphasize how these modifications affect oncogenic signaling pathways and the complex interplay between tumor cells and the surrounding stromal and immune cells. Furthermore, we explore the therapeutic potential of targeting lipidation mechanisms in cancer treatment and discuss prospects for developing novel anticancer strategies that disrupt lipidation-dependent signaling pathways. By bridging protein lipidation with the dynamics of the TME, our review provides novel insights into the complex relationship between them that drives tumor initiation and progression.
SAT-418-YI Indication of resmetirom in patients with metabolic dysfunction associated steatohepatitis in the real-world setting - data from the german SLD-registry
Authors: Eva Messer, David Petroff, Jörn M. Schattenberg, Stefan Zeuzem, Manfred von der Ohe, Leopold Ludwig, Münevver Demir, Heiner Wedemeyer, Thomas Berg, Wolf Peter Hofmann, Andreas Geier, Johannes Wiegand
Journal: Journal of Hepatology (2025)
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J.P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Mariko Harada-Shiba, Danielle L. Curcio, Annie Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Yong Huo, Michael Szarek, Violeta Balinskaite, Michael H. Davidson
Journal: New England Journal of Medicine (2025)

Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events. We conducted a multinational, randomized, placebo-controlled trial involving patients with heterozygous familial hypercholesterolemia or a history of atherosclerotic cardiovascular disease who were receiving maximum tolerated doses of lipid-lowering therapy. Patients with an LDL cholesterol level of 100 mg per deciliter or higher or a non-high-density lipoprotein (HDL) cholesterol level of 130 mg per deciliter or higher, as well as those with an LDL cholesterol level of 55 to 100 mg per deciliter or a non-HDL cholesterol level of 85 to 130 mg per deciliter and at least one additional cardiovascular risk factor, were eligible for inclusion. The patients were randomly assigned in a 2:1 ratio to receive either 10 mg of obicetrapib once daily or matching placebo for 365 days. The primary end point was the percent change in the LDL cholesterol level from baseline to day 84. A total of 2530 patients underwent randomization; 1686 patients were assigned to receive obicetrapib and 844 to receive placebo. The mean age of the patients was 65 years, 34% were women, and the mean baseline LDL cholesterol level was 98 mg per deciliter. The least-squares mean percent change from baseline to day 84 in the LDL cholesterol level was -29.9% (95% confidence interval [CI], -32.1 to -27.8) in the obicetrapib group, as compared with 2.7% (95% CI, -0.4 to 5.8) in the placebo group, for a between-group difference of -32.6 percentage points (95% CI, -35.8 to -29.5; P<0.001). The incidence of adverse events appeared to be similar in the two groups. Among patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were receiving maximum tolerated doses of lipid-lowering therapy and were at high risk for cardiovascular events, obicetrapib reduced LDL cholesterol levels by 29.9%. (Funded by NewAmsterdam Pharma; BROADWAY ClinicalTrials.gov number, NCT05142722.).
TOP-474 Bio-molecular characterization of albumin identifies predictors of disease severityand early mortality in severe alcohol associated hepatitis
Authors: Sushmita Pandey, Neha Sharma, Gaurav Tripathi, Vasundhra Bindal, Babu Mathew, Nupur Sharma, Sadam H Bhat, Sanju Yadav, Rimsha Rimsha, Manisha Yadav, Shvetank Sharma, Anju Katyal, Shiv Kumar Sarin, Jaswinder Maras
Journal: Journal of Hepatology (2025)
SAT-450 ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study
Authors: Rohit Loomba, Dimple Desai, Daniel Santillano, Kathryn Lucas, Naim Alkhouri, Guy W. Neff, Antonio Bianco, Eveline Bruinstroop, Stanley Wang, Kha Le, Megan Fitzgerald, Min Wu, Ifong Kan-Eng, Genevieve Harrington, Chris Burnett, Jen Rito, Doug Clark, Naqvi Mohammed, Meenakshi Venkatraman, Tse-I Lin, Sushmita Chanda, Hardean Achneck, Lawrence Blatt, Christos Mantzoros
Journal: Journal of Hepatology (2025)
SAT-325 Quantitative biliary metrics may add to predictive ability of liver stiffness in patients with primary sclerosing cholangitis
Authors: Aisha Alawi, Leila Amiri, Kristel Leung, Sarah Finnegan, Amy Herlihy, Elizabeth Shumbayawonda, Tom Davis, Bettina E. Hansen, Gideon M. Hirschfield, Kartik Jhaveri, Aliya Gulamhusein
Journal: Journal of Hepatology (2025)
SAT-006 Emergency department blood-borne virus screening and the revealed burden of hepatitis B-driven liver disease
Authors: Kartikeya Khanna, Mia Olsen, Nabiha Essaji, Susanne Johansen, Kathryn Oakes, Sam Douthwaite, Kosh Agarwal, Kate Childs, Bo Wang
Journal: Journal of Hepatology (2025)
FRI-381-YI Oncostatin M contributes to liver steatosis in experimental metabolic dysfunction - associated steatotic liver disease
Authors: Jessica Nurcis, Salvatore Sutti, Irene Varriale, Francesca Protopapa, Alessia Provera, Cristina Vecchio, Stefania Cannito, Beatrice Foglia, Marina Maggiora, Claudia Bocca, Emanuele Albano, Maurizio Parola, Erica Novo
Journal: Journal of Hepatology (2025)
WED-501 Prognostication of liver disease patients via ARFI-based liver stiffness measurement using the WFUMB “Rule-of-4” algorithm
Authors: Christian Sebesta, Georg Kramer, Nina Dominik, Benedikt Hofer, Lorenz Balcar, Paul Thöne, Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Till Schöchtner, Nicolas Balutsch, Friedrich Haimberger, Michael Trauner, Albert Friedrich Stättermayer, Mattias Mandorfer, Thomas Reiberger, David Bauer
Journal: Journal of Hepatology (2025)
FRI-038 Unraveling the liver immune rheostat: How contact-dependent regulation causes dysfunction of antigen-specific CD8 T cells over the course of chronic hepatitis B
Authors: Anna Fürst, Vincent Steinbacher, Hannah Wintersteller, Miriam Bosch, Ulrike Protzer, Dirk Wohlleber, Percy A. Knolle
Journal: Journal of Hepatology (2025)
RBC Membrane‐Camouflaged Nanosystem‐Mediated Synergistic Drug Combination for Enhanced Anti‐Tumor Therapy
Authors: Qian Cheng, Xuemei Zhong, Lu Deng, Xinling He, Miaoxizi Luo, Ruibing Wang, Jinming Zhang
Journal: Advanced Healthcare Materials (2025)

Abstract Achieving direct delivery of drugs to the tumor site is a prerequisite for successful drug development, necessitating that drug molecules be cell permeable. Numerous studies have shown that cell‐penetrating peptides (CPPs) can augment the efficacy of various therapeutic agents by enhancing cellular uptake, prompting their advancement into preclinical studies. However, the non‐specificity and cationic properties of CPPs impede their clinical application. Attributed to the easily accessible capacity and excellent biocompatibility of red blood cells (RBC), herein, an RBC membrane camouflaged, cell‐penetrating peptides R8‐(RRRRRRRR)based drug delivery system is constructed to achieve a synergistic combination of natural compounds triptolide (TP) and celastrol (Cel), thus precisely inducing tumor inhibition. The RBC membrane camouflaged nanosystem escaped from the reticuloendothelial system (RES) and is endocytosed by tumor cells mediated by R8. Released TP and Cel‐induced tumor cell apoptosis, reducing tumor metastasis invasion and triggering autophagy disorder in breast cancer and liver cancer. Overall, the biomimetic nanosystem realizes enhanced drug combination therapy with high‐level biosafety, which provides a facile strategy to improve the clinical application of CPPs‐based drug combinations.
SAT-175-YI Natural history of overt hepatic encephalopathy defining factors associated with progression, resolution and mortality
Authors: María Pilar Ballester, Anindro Bhattacharya, Ferran Aguilar, Francois Fenaille, Cristina Sanchez, Richard Moreau, Vicente Arroyo, Jonel Trebicka, Juan Antonio Carbonell-Asins, Christopher F. Rose, Rajiv Jalan, On behalf of the PREDICT Study Group and AMMON Consortium
Journal: Journal of Hepatology (2025)
SAT-316 Sustained HBsAg loss in HIV/HBV-coinfected patients is not a rare event under HBV-active ART even if a residual risk of viral reactivation and liver disease progression still persists over time
Authors: Romina Salpini, Alessandro Tavelli, Elena Bruzzesi, Lorenzo Piermatteo, Stefano D’Anna, Anna Carraro, Marta Camici, Chiara Papalini, Claudia Lazzaretti, Nicoletta Bobbio, Eugenio Milano, Roberto Rossotti, Vincenzo Malagnino, Massimo Puoti, Antonella d’Arminio Monforte, Valentina Svicher
Journal: Journal of Hepatology (2025)
SAT-158 Factors predicting response to long-term albumin administration and impact on survival in patients with decompensated cirrhosis. A single-centre real-world experience
Authors: Isabel Payeras, Ana Clemente, María Sasía, Luis Alberto Pérez, Adriana Ahumada, Diego Rincón, Magdalena Salcedo, Ana Matilla, Rafael Bañares, Sonia Alonso Lopez
Journal: Journal of Hepatology (2025)
SAT-470 Impact of diabetes mellitus on mortality in alcohol-related acute-on-chronic liver failure: a study from the AARC database
Authors: Ashish Kumar, Shiv Kumar Sarin, Rakhi Maiwall, Ashok Choudhury, Vinod Arora, Mohamed Rela, Dinesh Jothimani, Mamun Al-Mahtab, Harshad Devarbhavi, CE Eapen, Ashish Goel, Cesar Yaghi, Qin Ning, Tao Chen, Jidong Jia, Zhongping Duan, Saeed Sadiq Hamid, Amna Subhan, Wasim Jafri, Akash Shukla, Soek-Siam Tan, Dong Joon Kim, Anoop Saraya, Jinhua Hu, AJIT Sood, Omesh Goyal, Vandana Midha, Manoj Sahoo, Guan-Huei Lee, Sombat Treeprasertsuk, Kessarin Thanapirom, Ameet Mandot, Samir Shah, Ravikiran Maghade, Laurentius A. Lesmana, Hasmik Ghazinyan, Mohan Prasad V G, A.Kadir Dokmeci, Jose Sollano, Zaigham Abbas, Ananta Shrestha, George Lau, Diana Payawal, Gamal Shiha, Ajay Kumar Duseja, Sunil Taneja, Nipun Verma, Nagaraja Rao Padaki, Anand Kulkarni, Mithun Sharma, Fazal Karim, Radha Krishan Dhiman, Ajay Mishra, Shahinul Alam, Osamu Yokosuka, Dr. Debashis Chowdhury, Chandan Kedarisetty, Dr Sanjiv Saigal, Anil Arora, Praveen Sharma, Ghulam Nabi Yattoo, Abraham Koshy, Ajay Kumar, Mohammed Elbasiony, Pravin Rathi, Sudhir Maharshi, V.M Dayal, Ashish Kumar Jha, Kemal Fariz Kalista, Rino Gani, Man-Fung Yuen, Virendra Singh, Ayaskant Singh, Sargsyan Violeta, Chien-Hao Huang, Saurabh Mukewar, Shaojie Xin, Ruveena Bhavani, Charles Panackel, Sunil Dadhich, Sanjeev Sachdeva, Ajay Kumar, Sanatan Behera, Prabir Maji, Lubna Kamani, Hemamala Venugopal Saithanyamurthi, Dr. Joy Varghese, Pathik Parikh, P Javed, Neeraj Saraf, Narendra S Choudhary, Akash Roy, Mahesh Goenka, Chetan Kalal, Krishnadas Devadas, Gupse Adali, Janaka De Silva H
Journal: Journal of Hepatology (2025)
WED-194-YI Treatment response to terlipressin in patients with acute kidney injury - hepatorenal syndrome and preexisting chronic kidney disease – the german liver cirrhosis/CKD-Terli study group
Authors: Frank Erhard Uschner, Eva Maria Schleicher, Moritz Passenberg, Julian Pohl, Michael Praktiknjo, Anna Teresa Volk, Henrik Karbannek, Johannes Chang, Karsten Große, Charlotte Rohrer, Christian Labenz, Benjamin Maasoumy, Paul Jamme, Julian Cardinal von Widdern, Alexander Queck, Jonel Trebicka, Cornelius Engelmann, Jassin Rashidi-Alavijeh, Dominik Bettinger, Cristina Ripoll
Journal: Journal of Hepatology (2025)
SAT-294 Should EASL expand its 2017 treatment criteria for chronic hepatitis B virus infection to ineligible people: analysis from a UK- based cohort
Authors: Monika Prabhaker-Kaushal, Alexander Cole, Yusuke Shimakawa, Erwan Vo Quang, Ameet Dhar, Belinda Smith, Zebib Habtemariam, Shevanthi Nayagam, Ashley Brown, Maud Lemoine
Journal: Journal of Hepatology (2025)
FRI-488 Concomitant sarcopenia and myosteatosis in patients with cirrhosis is associated with longer recovery and mortality after liver transplantation
Authors: Ellina Lytvyak, Devika Shreekumar, Shagani Thisairajah, Maryam Motamedrad, Narmeen Umar, Glenda Meeberg, Norberto Sanchez-Fernandez, Alessandro Parente, Norman Kneteman, Khaled Dajani, Blaire Anderson, David Bigam, James Shapiro, Aldo J. Montano-Loza
Journal: Journal of Hepatology (2025)
FRI-172 Intraperitoneal administration of investigational drug VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosis
Authors: Olaf Tyc, Berenice Alard, Meriam Kabbaj, Jeremy Magnanensi, Martin Schulz, Sabine Klein, Robert Schierwagen, Sakina Sayah Jeanne, Stephanie Ferreira, Dean Hum, Bart Staels, Katharina Staufer, Jonel Trebicka, Frank Erhard Uschner
Journal: Journal of Hepatology (2025)
FRI-439 Shallow-deep neural networks reveal extracellular vesicles as robust biomarkers for liver steatosis stages S0 vs. S1-S3 in metabolic dysfunction-associated steatotic liver disease patients
Authors: Eleni-Myrto Trifylli, Athanasios Angelakis, Anastasios Kriebardis, Nikolaos Papadopoulos, Sotirios Fortis, Vasiliki Pantazatou, Ioannis Koskinas, Hariklia Kranidioti, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch
Journal: Journal of Hepatology (2025)
TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States
Authors: Shanghao Liu, Jie Shen, Ling Yang, Heng Wan, Jie Li, Chuan Liu, Jingli Gao, Wenjing Ni, Yilin Zhang, Lan Liu, Hua Liang, Yuping Chen, Jiawei Zhang, Yuqin Zhang, Hui Shi, Zhenyu Dai, Yijun Tang, Qing He, Wen-Hui Li, Feng Xie, Xiaosong Yan, Shenghong Ju, Huapeng Lin, Gao-Jun Teng, Frank Tacke, Xiaolong Qi
Journal: Journal of Hepatology (2025)
THU-087 TIGAR SUMOylation: a key modulator of metabolic balance in hepatocellular carcinoma
Authors: Carolina Conter, Claudia M. Rejano-Gordillo, Laura Mosca, Pietro Guerra, Sofia Lachiondo-Ortega, Leidy Estefanía Zapata-Pavas, Patricia Peña-Sanfelix, Miguel Angel Merlos Rodrigo, María Luz Martínez-Chantar
Journal: Journal of Hepatology (2025)
THU-070 Characterizing the differentiation and cellular heterogeneity of hepatic stellate cells derived from induced pluripotent stem cells
Authors: Zhengqing Xu, Raquel A. Martínez-García de La Torre, Maria Mercado, Raquel Ferrer-Lorente, Antonio Segovia-Zafra, Laura Zanatto, Silvia Ariño, Marc Miravet, Pau Sancho-Bru
Journal: Journal of Hepatology (2025)
SAT-520 Effective in vivo transplantation of revascularized porcine liver scaffolds in pigs for extended function over one month
Authors: Sandra Melitón Barbancho, Valeria Chiluiza, Pablo Royo Dachary, Helen Almeida, Javier Martínez-García, Álvaro Blanes-Rodríguez, Maria Lourdes Bengochea Martinez, Cristina Pastor, Pedro Baptista
Journal: Journal of Hepatology (2025)
FRI-067 Intrahepatic TCF-1+ T cells reside with myeloid cells in peribiliary lymphoid follicles, respond to the autoantigen pyruvate dehydrogenase complex E2 and T cell receptor stimulation
Authors: Rémi Fiancette, Scott Davies, Ayma Asif, Naomi Richardson, Sian Faustini, Jingwen Mao, Kayani Kayani, Amber Bozward, Ye Htun Oo
Journal: Journal of Hepatology (2025)
THU-200 Checkpoint inhibitor-induced liver injury in patients with advanced skin cancer: a single center experience
Authors: Antonio Liguori, Sebastiano Archilei, Laura Quattrini, Francesco Brunetti, Marisa Salvi, Giuseppe Marrone, Marco Biolato, Luca Miele, Maurizio Pompili, Alessandro Di Stefani, Antonio Gasbarrini, Ketty Peris, Antonio Grieco
Journal: Journal of Hepatology (2025)
WED-514 Prediction of esophageal varices in fontan associated liver disease (FALD)
Authors: Victoria Kusztos, Mayank Sharma, Blake Kassmeyer, Ryan Lennon, Sudhakar Venkatesh, Meng Yin, Alexander Egbe, Patrick S. Kamath, Moira Hilscher, Douglas Simonetto
Journal: Journal of Hepatology (2025)
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Authors: Ashish Sarraju, Danielle Brennan, Kierstyn Hayden, Amanda Stronczek, Anne C Goldberg, Erin D Michos, Darren K McGuire, Denise Mason, Grace Tercek, Stephen J Nicholls, Douglas Kling, Annie L Neild, John Kastelein, Michael Davidson, Marc Ditmarsch, Steven E Nissen
Journal: The Lancet (2025)
FRI-191 Modification of mortality risk scores with dynamic serum creatinine definition improves survival discrimination in patients with decompensated cirrhosis
Authors: Julian Allgeier, Nicholas Zeuzem, Alina Bauschen, Nikola Mareljic, Paul Jamme, Johannes Sauter, Mona Langer, Christiana Graf, Cristina Ripoll, Christian M. Lange
Journal: Journal of Hepatology (2025)
THU-494 PNPLA3 risk variant and shortened telomere are independent risk factors for alcohol related liver disease: an indian cohort study
Authors: Vaishali Yadav, S Muralikrishna Shasthry, Kanica Kaushal, Mohit Varshney, Satender Singh, Guresh Kumar, Vipin Yadav, Khushboo Agrawal, Nirupma Trehanpati, Shiv Kumar Sarin, Gayatri Ramakrishna
Journal: Journal of Hepatology (2025)
FRI-055-YI Inhibition of the lysophatidylcholine-autotaxin-lysophosphatidic acid axis restores monocytic pro-inflammatory cytokine production in patients with acute-on-chronic liver failure
Authors: Joseph Wilson, Roosey Sheth, Francesca Trovato, Rima Abdalla, Evangelos Triantafyllou, Mark Mcphail
Journal: Journal of Hepatology (2025)
TOP-189-YI Vibration-controlled transient elastography of the liver and the spleen for hepatic decompensation risk stratification in a european multicentre study of contemporary cACLD patients
Authors: Mathias Jachs, Paul Thöne, Aitor Odriozola, Fanny Turon, Lucile Moga, Luis Téllez, Fischer Petra, Dario Saltini, Wilhelmus J Kwanten, Maria Grasso, Elba Llop Herrera, Yuly Mendoza, Angelo Armandi, Carlos Pardo, Antonio Colecchia, Federico Ravaioli, Benjamin Maasoumy, Wim Laleman, José Presa, Jörn M. Schattenberg, Annalisa Berzigotti, José Luis Calleja Panero, Vincenza Calvaruso, Sven Francque, Filippo Schepis, Bogdan Procopet, Agustín Albillos, Pierre-Emmanuel Rautou, Juan Carlos García-Pagán, Angela Puente, Jose Fortea, Thomas Reiberger, Mattias Mandorfer
Journal: Journal of Hepatology (2025)
SAT-306 Assessment of hepatocarcinogenesis risk using CAMP-B and PAGE-B in patients with chronic hepatitis B
Authors: Masatsugu Ohara, Goki Suda, Takatsugu Tanaka, Shoichi Kitano, Naohiro Yasuura, Akimitsu Meno, Risako Kohya, Takashi Sasaki, Takashi Kitagataya, Masato Nakai, Takuya Sho, Naoya Sakamoto
Journal: Journal of Hepatology (2025)
FRI-181 Plasma interleukin-33 as a novel diagnostic marker for invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure: a prospective study
Authors: Lanyue Huang, Wei Liu, Yunhui Liu, Liang Chen, Meng Zhang, Yuxin Niu, Yuzhao Feng, QiuYu Cheng, Tingting Liu, Mi Song, Qin Ning, Tao Chen
Journal: Journal of Hepatology (2025)
FRI-155-YI The PPAR agonists Saroglitazar and Rosiglitazone provide hepatoprotection after APAP-induced liver injury in E2f1-/- mice
Authors: Paul Gomez-Jauregui, Francisco Gonzalez-Romero, Ane Ortiz-Palma, Beatriz Gómez Santos, Maider Apodaka-Biguri, Xabier Buque, Maria Crespo, Alfonso Mora, Mariana Mesquita, Igor Aurrekoetxea, Igotz Delgado, Ane Nieva-Zuluaga, Mikel Ruiz de Gauna, Idoia Fernández-Puertas, Natalia Sainz-Ramirez, Kendall Alfaro-Jiménez, Estibaliz Castillero, María Esther Irizar, Ainhoa Iglesias, Francisco Javier Cubero, Guadalupe Sabio, Ana Zubiaga, Patricia Aspichueta
Journal: Journal of Hepatology (2025)
OS-015 The burden of HDV chronic infection and the gaps in HDV screening across Europe: an urgent need to strengthen diagnostic strategies at pan-european level
Authors: Romina Salpini, Ivailo Alexiev, Leonardo Baiocchi, Leontina Banica, Josip Begovac, Brigita Benkoova, Shubhada Bopegamage, Carlotta Castelli, Cinzia Caudai, Stefano D’Anna, Tulin Demir, Carole Devaux, Andrea Di Lorenzo, Eva Heger, Rolf Kaiser, Naomi Kokkinos, Gema Fernández-Rivas, Katarina Gazdikova, Anna Maria Geretti, Elica Golkocheva-Markova, Ilaria Grossi, Ivana Lazarevic, Voichita Lazureanu, Karoline Leuzinger, Magnus Lindh, Josep Llibre, Maja Lunar, Jakub Mihale, Orna Mor, Dirk Nierhoff, Dan Otelea, Lorenzo Piermatteo, Mario Poljak, Anna Riccio, Maja Ruzic, Loredana Sarmati, Giulia Torre, Ana Maria Tudor, Andrei Vata, Dilara Yildiran, Maurizio Zazzi, Anne Marie Wensing, Valentina Svicher
Journal: Journal of Hepatology (2025)
OS-027-YI A human cirrhosis single-cell atlas identifies a pro-inflammatory subpopulation of scar-associated macrophages as a therapeutic target for liver fibrosis
Authors: Kexin Kong, Eleni Papachristoforou, Fabio Colella, Juliet Luft, Jacky Tam, Malgorzata Grzelka, Max A. Hammer, Stefan Veizades, George Finney, Ginevra Pistocchi, Catalina A. Vallejos, Laura J. Pallett, Prakash Ramachandran
Journal: Journal of Hepatology (2025)
WED-223 Colonization with multidrug resistant organisms is associated with poor outcomes in patients with decompensated cirrhosis of liver: a tertiary care center experience
Authors: Manasa Alla, Ankit Mittal, Shantan Venishetty, Anand Kulkarni, Mithun Sharma, Sowmya Iyengar, Haripriya Reddy, Harshith Kadnur, Nagaraja Padaki, Nageshwar Reddy
Journal: Journal of Hepatology (2025)
OS-085-YI Clinical prediction model with good discriminative capacity for mortality risk in autoimmune hepatitis
Authors: Charlotte Slooter, Floris van den Brand, Ana Lleo, Francesca Colapietro, Marco Lenzi, Paolo Muratori, Nanda Kerkar, George Dalekos, Kalliopi Zachou, Maria Isabel Lucena, Mercedes Robles-Díaz, Daniel E. Di Zeo-Sánchez, Raul J. Andrade, Aldo J. Montano-Loza, Ellina Lytvyak, Martijn Heymans, Olga Falco, Alessio Gerussi, Pietro Invernizzi, Guilherme Macedo, Gerd Bouma, Rodrigo Liberal, Joost PH Drenth, Ynto de Boer
Journal: Journal of Hepatology (2025)
FRI-385 High-throughput in vivo pooled screening can identify therapies applicable across the spectrum of metabolic dysfunction-associated steatohepatitis disease severity
Authors: Joanne Hsieh, Vinay Kartha, Jingshu Chen, Hikaru Miyazaki, Shengping Wang, Ian Driver, Chris Carrico, Daniel Fuentes, Linda Chio, Dimitry Popov, Jessica Nonora, Arnav Gupta, Alex Araki, Smitha Shambhu, Gayathri Donepudi, Chris Towne, Francisco LePort, Martin Borch Jensen
Journal: Journal of Hepatology (2025)
WED-106 Impact of metformin on the prevention of hepatocarcinoma in chronic hepatitis C with advanced fibrosis after sustained virologic response
Authors: Henar Calvo Sánchez, Lorena Jara, Irene Villarino, Ruben Alvarado, Marta Quiñones, Vanessa Díaz, Maria Luisa Gutiérrez, Joaquín Míquel, Miguel Torralba, Sonia Albertos Rubio, Myriam Catalá, José Gómez, Oscar Barquero-Pérez, Conrado Fernández- Rodríguez, Juan Ramón Larrubia
Journal: Journal of Hepatology (2025)